Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (21-30 of 484) with videos related to

Pageof 49
Sort By:
Current Rheumatology Reports|May 16, 2007
Therapy of pulmonary arterial hypertension in systemic sclerosis: an updateChristopher P Denton, Svetlana I Nihtyanova
Nature Reviews. Rheumatology|April 10, 2013
Targeted therapies for systemic sclerosisChristopher P Denton, Voon H Ong
The Lancet. Respiratory Medicine|March 2, 2020
Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung diseaseChristopher P Denton, Voon H Ong
The Lancet. Rheumatology|January 31, 2024
When the game changes: efficacy of rituximab in systemic sclerosisVoon H Ong, Christopher P Denton
Arthritis & Rheumatology (Hoboken, N.J.)|March 8, 2018
ReplyChristopher P Denton, Ariane L Herrick
Rheumatic Diseases Clinics of North America|July 27, 2015
The Pathogenesis of Systemic SclerosisEdward P Stern, Christopher P Denton
The Journal of Rheumatology|June 13, 2017
Scleroderma Lung Involvement, Autoantibodies, and Outcome Prediction: The Confounding Effect of TimeSvetlana I Nihtyanova, Christopher P Denton
Current Opinion in Rheumatology|September 20, 2023
Enrichment strategies for clinical trials targeting skin fibrosis and interstitial lung disease in systemic sclerosisAriane L Herrick, Christopher P Denton
Autoimmunity Reviews|July 13, 2004
Transgenic analysis of scleroderma: understanding key pathogenic events in vivoChristopher P Denton, David J Abraham
Trends in Immunology|September 20, 2005
Targeted therapy comes of age in sclerodermaChristopher P Denton, Carol M Black
Pageof 49

Showing results (21-30 of 484) with videos related to

Sort By:
Pageof 49
Current Rheumatology Reports|May 16, 2007
Therapy of pulmonary arterial hypertension in systemic sclerosis: an updateChristopher P Denton, Svetlana I Nihtyanova
Nature Reviews. Rheumatology|April 10, 2013
Targeted therapies for systemic sclerosisChristopher P Denton, Voon H Ong
The Lancet. Respiratory Medicine|March 2, 2020
Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung diseaseChristopher P Denton, Voon H Ong
The Lancet. Rheumatology|January 31, 2024
When the game changes: efficacy of rituximab in systemic sclerosisVoon H Ong, Christopher P Denton
Arthritis & Rheumatology (Hoboken, N.J.)|March 8, 2018
ReplyChristopher P Denton, Ariane L Herrick
Rheumatic Diseases Clinics of North America|July 27, 2015
The Pathogenesis of Systemic SclerosisEdward P Stern, Christopher P Denton
The Journal of Rheumatology|June 13, 2017
Scleroderma Lung Involvement, Autoantibodies, and Outcome Prediction: The Confounding Effect of TimeSvetlana I Nihtyanova, Christopher P Denton
Current Opinion in Rheumatology|September 20, 2023
Enrichment strategies for clinical trials targeting skin fibrosis and interstitial lung disease in systemic sclerosisAriane L Herrick, Christopher P Denton
Autoimmunity Reviews|July 13, 2004
Transgenic analysis of scleroderma: understanding key pathogenic events in vivoChristopher P Denton, David J Abraham
Trends in Immunology|September 20, 2005
Targeted therapy comes of age in sclerodermaChristopher P Denton, Carol M Black
Pageof 49